Table 3 |
|||||||||
|
Protein levels which characterized advanced PDAC stage |
|||||||||
|
Number of specimens (%) |
|||||||||
|
|
|||||||||
|
Marker |
Low protein level |
High protein level |
p-value |
||||||
|
|
|||||||||
|
I |
II |
III |
IV |
I |
II |
III |
IV |
||
|
|
|||||||||
|
Cytoplasm |
|||||||||
|
PTEN |
1 (7) |
8 (53) |
6 (40) |
0 |
1 (9) |
0 |
8 (73) |
2 (18) |
0.01 |
|
βCAT |
1 (6) |
8 (50) |
5 (31) |
2 (13) |
0 |
1 (10) |
9 (90) |
0 |
0.04 |
|
p-NFκB |
1 (5) |
9 (47) |
7 (37) |
2(11) |
0 |
0 |
5 (100) |
0 |
0.05 |
|
Nucleus |
|||||||||
|
Y705p-STAT3 |
0 |
0 |
6 (75) |
2 (25) |
1 (6) |
9 (50) |
8 (44) |
0 |
0.01 |
|
p-GSK3β |
1 (5) |
9 (45) |
8 (40) |
2 (10) |
0 |
0 |
6 (100) |
0 |
0.05 |
|
|
|||||||||
|
Listed are tumors of stage I to IV, and their proportions (%) in low/high protein levels. Advanced PDAC stage (III and IV) associated with high protein levels (PTEN, βCAT, p-NFκB and p-GSK3β) and low p-STAT3 levels (Fisher's exact test, p ≤ 0.05). |
|||||||||
|
Pham et al. BMC Cancer 2008 8:43 doi:10.1186/1471-2407-8-43 |
|||||||||
